Cybin is to meet with the UK’s Medical and Healthcare Products Regulatory Agency (MHRA) to discuss its lead psychedelic candidate CYB003 as a treatment for Major...
Psyched Wellness presented its proprietary extract of the Amanita Muscaria mushroom, AME-1, to Health Canada representatives to discuss the evidence required in support of a Class...
Ketamine One Capital and Cognetivity Neurosciences have entered into a partnership to study and develop assessments for depression and post-traumatic stress disorder (PTSD).
MYND has received the funding that will go towards its research and development into the effects of psilocybin for treating brain and central nervous system diseases.
The clinical trial is aiming to understand how psilocybin alters brain function in order to improve treatment options for mental illness.
The US Food and Drug Administration (FDA) has given authorisation for a Phase II clinical trial to evaluate psychedelic-assisted psychotherapy for frontline clinicians who are experiencing...
UK-based psychedelics company Albert Labs has received conditional approval for the listing of its common shares on the Canadian Securities Exchange (CSE).
As regulation surrounding psychedelics develops across the globe, Numinus Wellness has created a toxicity and potency screening test that will facilitate safety and efficacy testing of...
Findings from a new study give insight into how psychedelic substances may relieve symptoms of mental health conditions.
Clearmind Medicine has signed an R&D agreement with Bar-Ilan University to explore the efficacy of its compound for the treatment of addiction.
